Two methods for measuring cross-reactivity could boost the safety of T-cell therapies.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Sewell, A.K. Nat. Rev. Immunol. 12, 669–677 (2012).
Birnbaum, M.E. et al. Cell 157, 1073–1087 (2014).
Zhang, S. et al. Nat. Biotechnol. 36, 1156–1159 (2018).
Bentzen, A.K. et al. Nat. Biotechnol. 36, 1191–1196 (2018).
Altman, J.D. et al. Science 274, 94–96 (1996).
Newell, E.W. et al. Nat. Biotechnol. 31, 623–629 (2013).
Huang, J. et al. Proc. Natl. Acad. Sci. USA 113, E1890–E1897 (2016).
Dolton, G. et al. Front. Immunol. 9, 1378 (2018).
Bentzen, A.K. et al. Nat. Biotechnol. 34, 1037–1045 (2016).
Rodenko, B. et al. Nat. Protoc. 1, 1120–1132 (2006).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Natarajan, A., Krogsgaard, M. The myriad targets of a T cell. Nat Biotechnol 36, 1152–1154 (2018). https://doi.org/10.1038/nbt.4309
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt.4309